Literature DB >> 32719186

Conservative management of 154 patients with idiopathic granulomatous mastitis: Simple is better?

Sema Yuksekdag, Abdullah Yildiz, Kadir Yildirak, Gulcicek Ayranci, Esin Cibiroglu, Fikret Ezberci, Ethem Unal.   

Abstract

PURPOSE: Both the aetiology and treatment of idiopathic granulomatous mastitis (IGM) is controversial and unnecessary resections can lead to over-treatment in such a benign disease. Our aim was to report our experience in patients with IGM managed mainly with conservative methods, such as antibiotics, drainages and corticosteroids.
MATERIAL AND METHODS: Pathology database from 2008 to 2018 was reviewed retrospectively. Demographics and symptoms were documented from patient charts. Follow-up information was obtained from clinical reviews, and severity and duration of symptoms were documented. All data were transferred to Excel file and the parameters were compared.
RESULTS: All 154 patients were women. Mean age was 35.9 years. Empiric broad-spectrum antibiotic, abscess drainage and steroid treatments were seen to be successful in most of the cases (95.4%). In patients with limited regression (2.5%) or persistant lesions (1.9%), a second cycle was employed with a total regression rate of 100%. Recurrence was seen one or two times in 23 (14.9%) and 2 (1.2%) patients in a mean follow-up period of 5.3 years. The average time of recurrence was 2.5 years (range, 9-74 months).
CONCLUSIONS: Conservative management could be efficacious for IGM, and less and simpler can be enough to achieve more effective results. KEY WORDS: Abscess drainage, Antibiotics Idiopathic granulomatous mastitis (IGM), Conservative management, Corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32719186

Source DB:  PubMed          Journal:  Ann Ital Chir        ISSN: 0003-469X            Impact factor:   0.766


  1 in total

1.  What are the new findings with regard to the mysterious disease idiopathic granulomatous mastitis?

Authors:  Hande Koksal
Journal:  Surg Today       Date:  2021-01-28       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.